Dale Boger

Biography

 Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and his Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey. He returned to the University of Kansas as a member of the faculty in the Department of Medicinal Chemistry (1979-1985), moved to the Department of Chemistry at Purdue University (1985-1991), and joined the faculty in the newly created Department of Chemistry at The Scripps Research Institute (1991-present) as the Richard and Alice Cramer Professor of Chemistry. Professor Boger is internationally recognized for his work in organic synthesis, medicinal chemistry, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, and combinatorial chemistry and has made seminal contributions to the understanding of the interaction of biologically active molecules with their targets (e.g., DNA-drug interactions of naturally occurring antitumor drugs, glycopeptide antibiotic binding with bacterial cell wall precursors). He was a founder of CombiChem, a long term consultant to several major pharmaceutical companies (Dupont/Dupont-Merck, J&J), a Scientific Advisory Board member for many biotech firms (Rib-X, Conforma, Neurocrine, 3D Pharmecueticals), has served as an advisor to more than 50 PhD and 150 postdoctoral students, and is the coauthor of more than 500 publications and 2 books. He was the founder Editor and continues to serve as the Editor-in-Chief for Bioorganic and Medicinal Chemistry Letters.

Research Interest

 Dale Boger received his B.Sc. in chemistry from the University of Kansas, Lawrence, Kansas (1975, with highest distinction and honors in chemistry) and his Ph.D. in chemistry from Harvard University (1980) under the direction of E. J. Corey. He returned to the University of Kansas as a member of the faculty in the Department of Medicinal Chemistry (1979-1985), moved to the Department of Chemistry at Purdue University (1985-1991), and joined the faculty in the newly created Department of Chemistry at The Scripps Research Institute (1991-present) as the Richard and Alice Cramer Professor of Chemistry. Professor Boger is internationally recognized for his work in organic synthesis, medicinal chemistry, heterocyclic chemistry, natural products total synthesis and biological evaluation, synthetic methodology development, and combinatorial chemistry and has made seminal contributions to the understanding of the interaction of biologically active molecules with their targets (e.g., DNA-drug interactions of naturally occurring antitumor drugs, glycopeptide antibiotic binding with bacterial cell wall precursors). He was a founder of CombiChem, a long term consultant to several major pharmaceutical companies (Dupont/Dupont-Merck, J&J), a Scientific Advisory Board member for many biotech firms (Rib-X, Conforma, Neurocrine, 3D Pharmecueticals), has served as an advisor to more than 50 PhD and 150 postdoctoral students, and is the coauthor of more than 500 publications and 2 books. He was the founder Editor and continues to serve as the Editor-in-Chief for Bioorganic and Medicinal Chemistry Letters.